Results 11 to 20 of about 152,178 (350)

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Molecular Cancer, 2022
Background Approximate 25% HER2-positive (HER2+) breast cancer (BC) patients treated with trastuzumab recurred rapidly. However, the mechanisms underlying trastuzumab resistance remained largely unclear.
Yun Ling, Gehao Liang, Qun Lin, Xiaolin Fang, Qing Luo, Yinghuan Cen, Maryam Mehrpour, Ahmed Hamai, Zihao Liu, Yu Shi, Juanmei Li, Wanyi Lin, Shijie Jia, Wenqian Yang, Qiang Liu, Erwei Song, Jun Li, Chang Gong   +17 more
doaj   +2 more sources

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents

Frontiers in Oncology, 2022
Trastuzumab is a standard molecular targeted therapy for human epidermal growth factor receptor 2(HER2) -positive breast cancer, which can significantly improve the survival of patients with this molecular subtype of breast cancer.
Zhen-hao Wang, Zhen-hao Wang, Zhuo-qun Zheng, Shi−cheng Jia, Shu-ni Liu, Xiao-fen Xiao, Xiao-fen Xiao, Guan-yuan Chen, Guan-yuan Chen, Wei-quan Liang, Wei-quan Liang, Xiao-feng Lu, Xiao-feng Lu   +12 more
doaj   +2 more sources

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

New England Journal of Medicine, 2022
METHODS We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an
S. Modi, W. Jacot, T. Yamashita, J. Sohn, M. Vidal, E. Tokunaga, J. Tsurutani, N. Ueno, A. Prat, Y. Chae, K. Lee, N. Niikura, Yeon-Hee Park, Bing-he Xu, Xiao-juan Wang, M. Gil-Gil, Wei Li, J. Pierga, S. Im, H. Moore, H. Rugo, R. Yerushalmi, F. Zagouri, A. Gombos, Sung-Bae Kim, Qiang Liu, T. Luo, C. Saura, P. Schmid, T. Sun, D. Gambhire, L. Yung, Yibin Wang, Jasmeet Singh, P. Vitazka, G. Meinhardt, N. Harbeck, D. Cameron   +37 more
semanticscholar   +1 more source

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and
J. Cortés, Sung-Bae Kim, Wei-Pang Chung, S. Im, Yeon-Hee Park, R. Hegg, Min Hwan Kim, L. Tseng, V. Petry, Chi-Feng Chung, H. Iwata, E. Hamilton, G. Curigliano, Bing-he Xu, Chiun-Sheng Huang, J. Kim, J. Chiu, J. Pedrini, Caleb Lee, Yali Liu, J. Cathcart, E. Bako, S. Verma, S. Hurvitz   +23 more
semanticscholar   +1 more source

Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

Breast Cancer Research, 2020
Background ErbB2/HER2 oncoprotein often drives breast cancers (BCs) which are treated with the anti-ErbB2 antibody trastuzumab. The efficacy of trastuzumab-based metastatic BC therapies is routinely assessed by imaging studies.
Arik Durcker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis, Kirill V. Rosen   +8 more
doaj   +1 more source

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2021
BACKGROUND Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC).
Bob T. Li, E. Smit, Y. Goto, K. Nakagawa, H. Udagawa, J. Mazières, M. Nagasaka, L. Bazhenova, A. Saltos, E. Felip, J. Pacheco, M. Pérol, L. Paz-Ares, K. Saxena, R. Shiga, Yingkai Cheng, S. Acharyya, P. Vitazka, J. Shahidi, D. Planchard, P. Jänne   +20 more
semanticscholar   +1 more source

Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR

Breast Cancer Research, 2023
Background Breast cancer (BC) is the most common malignant disease in female patients worldwide. In HER-2+ BC patients, trastuzumab therapy is associated with a better prognosis.
Cuiwei Liu, Chong Lu, Lamu Yixi, Jiaxing Hong, Fang Dong, Shengnan Ruan, Ting Hu, Xiangwang Zhao   +7 more
doaj   +1 more source

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Biomolecules & Biomedicine, 2022
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma.
Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Muhammed Mustafa Atci, Atakan Topçu, Gökhan Uçar, Baran Akagündüz, Musa Bariş Aykan, Miraç Özen, Naziyet Köse Baytemur, Melike Özçelik, Elif Şahin , Denizcan Güven , Serkan Menekşe, Naziye Ak, Fatih Teker, Engin Kut, Teoman Şakalar, Özkan Alan, Turgut Kaçan , Nazim Serdar Turhal, Saadettin Kiliçkap, Sema Türker , Mehmet Ali Nahit Şendur, Osman Köstek, Mustafa Karaağaç , Abdullah Sakin , Haci Mehmet Türk, Dilek Çağlayan , Şener Cihan, Yusuf Açikgöz , Doğan Uncu   +33 more
doaj   +1 more source

A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity

EBioMedicine, 2020
Background: Pertuzumab is currently used in combination with trastuzumab as the first-line treatment for HER2-positive metastatic breast cancer. However, pertuzumab was originally developed independently from trastuzumab and was later incidentally found ...
Xiaoyu Ding, Wanjian Gu, Yujie Zhong, Xiaoyao Hao, Jinyu Liu, Shukai Xia, Lan Luo, Mingjiu Chen, Chunni Zhang   +8 more
doaj   +1 more source

Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer

Cancer Communications, 2023
Trastuzumab is a first‐line targeted therapy for human epidermal growth factor receptor‐2 (HER2)‐positive gastric cancer. However, the inevitable occurrence of acquired trastuzumab resistance limits the drug benefit, and there is currently no effective ...
Xingbin Hu, Zhenfeng Ma, Beibei Xu, Shulong Li, Z. Yao, B. Liang, Jiao Wang, W. Liao, Li Lin, Chunlin Wang, Siting Zheng, Qijing Wu, Qiong Huang, Le Yu, Fenghua Wang, Min Shi   +15 more
semanticscholar   +1 more source